electroCore, Inc.

Overview

<section> <heading>How the company got here</heading> <body_content> electroCore was founded in 2005 by a group of individuals who believed in the potential of neuromodulation, a way to influence nerve activity, to offer safer and more effective treatments for various conditions. Their initial focus was on developing non-invasive vagus nerve stimulation (nVNS) technology, which they discovered could be delivered without surgery. A key breakthrough came in 2010 with the development of gammaCore, a device that made nVNS therapy more accessible. The company went public in 2018, raising $78 million in an initial public offering (IPO). In recent years, electroCore has expanded its product line through acquisitions, such as the purchase of the Quell electrical nerve stimulation platform in 2025. </body_content> </section> <section> <heading>What it actually does</heading> <body_content> electroCore is a bioelectronic technology company that develops and sells devices using non-invasive vagus nerve stimulation (nVNS). The vagus nerve is a major nerve that runs from the brain to the abdomen and plays a role in many bodily functions. By stimulating this nerve through the skin, electroCore's devices aim to help manage various health conditions and promote general wellness. Their technology is used in both prescription medical devices and consumer wellness products. </body_content> </section> <section> <heading>Prescription Medical Devices</heading> <body_content> This business line focuses on medical devices that require a prescription from a healthcare professional. The flagship product here is gammaCore, a handheld device that uses non-invasive vagus nerve stimulation (nVNS). It is prescribed for the acute treatment of pain associated with conditions like migraine and episodic cluster headaches. gammaCore is also being explored for other neurological and respiratory conditions. The company also offers gammaCore Sapphire, a portable and rechargeable version of the device. </body_content> </section> <section> <heading>Consumer Wellness Products</heading> <body_content> This part of the business offers devices for general wellness and human performance that do not require a prescription. Truvaga is a personal-use consumer electronics product designed to help people feel calmer, think clearer, and sleep better. Truvaga Plus is an app-enabled version of this product. TAC-STIM is another device in this category, specifically designed for human performance and being explored for use by military personnel and first responders. This segment also includes the Quell Fibromyalgia device, acquired in 2025, which is an FDA-authorized wearable neuromodulation device to help reduce fibromyalgia symptoms. </body_content> </section> <section> <heading>What management is betting on now</heading> <body_content> electroCore's current strategy centers on three main pillars: expanding sales within covered entities (like the U.S. Department of Veterans Affairs), advancing their leadership in non-invasive vagus nerve stimulation (nVNS) through clinical research, and growing their presence in the consumer wellness market. Management is focused on achieving operational and financial improvements, including targeting revenue growth and positive adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization – a measure of a company's profitability). They are also pursuing new medical indications for their devices, such as chemotherapy-induced peripheral neuropathy and exploring label expansions for conditions like PTSD and mild traumatic brain injury. </body_content> </section>